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Patient Perceptions of Epinephrine Auto-Injectors: Exploring Barriers to Use  
Abstract: 297 words 
Background: In recent years, government initiatives have proposed that patient self-
care should serve as a key resource in response to the anticipated increase in global 
demand for health care. However, if patients are to be empowered as self-carers, 
barriers to engagement must be identified and overcome. Anaphylaxis is an 
increasingly common life threatening allergic reaction. Patients at risk of anaphylaxis 
are prescribed epinephrine auto-injectors and play a crucial role in delivering their 
own care and management of this condition. One key recommendation is that 
patients routinely carry an epinephrine auto-injector with them, and deploy the device 
when needed. However, only a small proportion of patients that require epinephrine 
actually receive it. 
Objective: To explore the reasons why patients who have been prescribed 
epinephrine auto-injectors fail to adhere to self-care and management 
recommendations. 
Methods: In-depth interviews with 15 adults who have been prescribed epinephrine 
auto-injectors were carried out to explore the barriers that exist in the provision of 
effective self-care and management of anaphylaxis. 
Results: Inconsistent health professional advice, perceived stigma of carrying a 
‘weapon-like’ device, poor device design and limited patient training were identified 
as barriers to carriage or use. Patients were reluctant to carry devices in public 
because of perceived and observed stigma and suspicion. They were happy to 
ignore expiry dates and some participants were confident that the emergency 
services would provide them with the appropriate care they needed, and therefore 
did not carry the device in urban areas. 
Conclusions and clinical implications: Improved training of patients, the public 
and health professionals around both the carriage and use of auto-injectors are 
areas for urgent attention if improved levels of self-care are to be attained. The 
design of epinephrine auto-injectors should also receive attention as patients often 
fail to carry them due to size and aesthetics. 
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INTRODUCTION 
With an anticipated rise in demand for health care resources (1-3), government 
initiatives see patient self-care and management as one of the few areas in which 
there still remains capacity for reducing costs whilst improving quality of service 
provision (4, 5). However, if the potential benefits in making a transition towards self-
care are to be fully realised, it is crucial that patients are able to deliver their self-care 
and management of this condition effectively (6). In-depth qualitative studies can 
assist in understanding the barriers that exist to patient engagement in the delivery 
of effective self-care and management (7), to provide insights into the self-care 
strategies that patients use for specific conditions/settings and suggest how these 
may be improved (8, 9). 
Anaphylaxis is a life threatening allergic reaction which affects the respiratory and/or 
cardiovascular systems (10). Whilst anaphylaxis may be triggered by exposure to 
latex rubber, insect venom and medication, the most common cause is exposure to 
foods including peanuts, nuts, fish, milk and eggs (11). The incidence of anaphylaxis 
has risen dramatically in recent years as reflected by a 7 fold increase in 
anaphylaxis-related UK hospital admissions between 1990/1 and 2003/4(12). The 
treatment of anaphylaxis is a prompt intramuscular injection of epinephrine, typically 
administered by the patient themselves. It is therefore not surprising that  
prescriptions of epinephrine auto-injectors (EAIs) have risen with 10,700 
prescriptions being issued in England in 2001, to 21,100 in 2005 (13). Patients 
considered at risk of anaphylaxis are prescribed at least one EAI, which in 
accordance with self-care and management best practice for this condition, is to be 
carried by the patient at all times so that the device is readily available for rapid self-
treatment when necessary (14). It is widely accepted that not having an EAI 
available at the scene of a severe anaphylaxis event puts the patient at significant 
risk of a fatal outcome (15).  
A key component to ensuring anaphylaxis patients’ needs are met is to ensure that 
allergy is thought of as a chronic condition (16). As with the majority of chronic 
conditions, key elements in the day-to-day management of anaphylaxis rely on the 
patient providing self-care to remain well and to be in a position to manage 
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symptoms should they arise (17). Importantly there are characteristics of anaphylaxis 
that differ from that of most chronic conditions, which in turn impact on care 
strategies. As long as the patient avoids the responsible allergen, they remain 
entirely well. Some patients may only have had a severe reaction in early childhood 
which they cannot remember, and through successful allergen avoidance they may 
not have used their emergency treatments for some decades. However, they are at 
constant risk of a life-threatening reaction, should avoidance strategies fail, and 
continual vigilance and an ability to implement an emergency management plan at 
an unpredictable time is a daily requirement.  
There is a lack of consensus in existing literature relating to the definition and scope 
of meaning of the term patient self-care and management (18). In this study, patient 
self-care and management is defined within the context of theory relating to 
management of chronic conditions; specifically within the emerging ‘patient-
practitioner partnership paradigm’ (19). This paradigm suggests that patients 
managing chronic conditions should be recognised as experts on their own lives and 
should be their own primary care providers (20); the overriding role of the health 
professional within this is to act as a consultant and to support patients in managing 
their condition (21). Recognising and enabling patients to take the role of an expert 
provides the opportunity for patients to take responsibility, manage, problem solve, 
and make decisions about their own care. This is sometimes referred to as patient 
empowerment within this paradigm (22). In order to ensure patients are able to fulfil 
their expert self-caring role effectively, and to ensure a positive patient-practitioner 
care relationship is realised, two key enabling factors must be accommodated (19):  
1) Provision of collaborative care: Recognition that patients have expertise of 
similar importance to that of health care professionals which are fully 
incorporated into the care delivery strategy. 
2) Provision of self-management education: Patients are supported by health 
care professionals to develop problem solving skills, which enable them to 
make informed decisions about their self-care and management. 
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Enabling patients to deliver effective self-care and management of chronic conditions 
has been shown to have a number of benefits including improvement of clinical 
outcomes (23) and in some cases reducing the overall cost of care (24). 
Although EAIs have been designed to be used as self-treatment devices by patients 
there is evidence to suggest that patients often do not engage in appropriate self-
care and management practices, such as the carriage and use of the device when 
necessary (25, 26). A study of fatal anaphylactic reactions revealed that only 10% of 
individuals actually had epinephrine to hand when it was required (27), and even 
when the device is to hand, it is often not used (28, 29).  
Despite the serious consequences of not having such a device to hand, there is a 
lack of research that considers the experiences, attitudes and strategies patients use 
in the delivery of care and the management of this condition. To the best of our 
knowledge, little research has been carried out to specifically explore, from the adult 
patients’ perspective, what patients motivations are for carriage or non-carriage of 
EAIs and/or their deployment/non-deployment at appropriate times. The limited 
research that does exist includes a study of issues related to the use of EAIs by 
adolescents (30) and exploring the psychosocial impact of anaphylaxis on young 
people (31), in which some initial insights are provided. For example, one participant 
in the latter study indicated that size of the device puts them off carrying it, and 
another participant suggested it is not easy to know how best to carry the device 
when taking it out and about. More generally, ensuring that medical devices are well 
designed and usable has been shown to have significant benefits including 
increased adherence for a wide range of users (32).  
This study aims to investigate the experiences of adults who have been prescribed 
EAIs, to better understand the barriers, from a patient perspective, to adhering to the 
self-care and management best practice recommendation of carrying the EAI at all 
times and its deployment when needed. Furthermore, taking into account the nature 
of these barriers, this study discusses whether improved levels of collaborative care 
and self-management education may go some way to help overcome the observed 
barriers to adherence.  
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METHODS 
Participants 
A convenience sampling strategy was used to identify participants eligible to take 
part in this study. The inclusion criteria were adults between the age of 18 and 65 
living in the South East of England, who reported to had been prescribed an EAI. A 
two-fold recruitment strategy was used. In the first instance, an email was sent out to 
all staff and students at Brunel University, inviting them to participate. Furthermore, 
an advertisement was placed in two freely circulated London newspapers, which 
also invited users to participate in our study. Severity of a participant’s allergic 
reaction was graded using a classification previously used for peanut allergy (33). 
Eligible participants that responded to the university email and newspaper advert 
were then incrementally invited to take part in the interview sessions. Recruitment of 
participants for Interview ceased with data saturation, that is, when the researcher 
leading the analysis (AM) observed a clear pattern emerging in participant responses 
and subsequent responses appeared to become repetitious with no new themes 
being identified (34). 
Semi-structured interviews and data analysis 
In-depth semi-structured interviews and the completion of a brief questionnaire were 
carried out on a one-to-one basis with each participant. Interviews were conducted 
by the first author at various locations throughout London, according to the 
requirements of the participants. Consent was obtained to record interviews with a 
digital voice recorder. 
The questionnaire collected basic demographics and information relating to each 
participant’s allergy. In the subsequent interview, participants were asked to discuss 
more generally their experiences as a carrier and/or user of the EAI, their 
motivations for carrying or not carrying the device, the situations in which they carry 
or do not carry their EAIs, the factors that affect whether or not they carry the device, 
and the design of the device, including which aspects the device design they would 
change if they could. Other topics discussed included friends and family’s thoughts 
about their allergy and the EAI. Template analysis was used to analyse the interview 
data. This is a form of thematic analysis, which involves development of a coding 
template that represents a summary of the themes that are seen by the 
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researcher(s) as being of importance within the data set (35). Analysis often begins 
with some a priori themes/codes that are of interest to the researcher, in this case, 
the interview data was approached with the broad aim of exploring factors that are 
related to and influence adherence with the EAI. Therefore, the approach taken in 
the analysis of this data is in line with what Madhill et al. (36) refer to as the 
‘contextual constructivist’ position. In this case, it is accepted that there are many 
interpretations that may be made of a given phenomenon, which depends upon the 
focus of the researcher, and the context in which the research is carried out. Hence, 
the themes that emerge as a result of the analysis are partly a product of these 
factors. 
As an initial step, all interview recordings were transcribed verbatim into text format 
by a trained transcriber. The textual dataset in its entirety was perused to 
conceptualise the overarching themes that existed at a high-level. The dataset was 
then perused for a second time, and sections of the text that corresponded with the 
focus of the research questions were taken note of. This process was carried out for 
the first three of the 15 interviews, after which, a number of over-arching themes 
representing the content within and across interviews was proposed as an initial 
coding template. Segments of text that corresponded with new themes as well as a 
priori themes were taken note of. The remainder of the dataset was then examined 
iteratively, enabling themes and sub-themes to be developed and modified as a 
result of carefully considering the contents of each transcript. This process was 
carried out by the first and second authors, who discussed inconsistencies where 
these arose, until a clear consensus of the main themes was reached (37). When no 
further refinement of the categorisation could be derived, a final template 
representing the themes and sub-themes identified within the full data set was 
produced, which was linked to the words of the respondents as they were presented 
in interview. For a detailed description of the thematic template analysis process, see 
King (35), and similarly for the thematic analysis process, see Joffe and Yardley  (38) 
and Silverman (39).  
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Ethical considerations 
The study was reviewed and approved by the Brunel University Research Ethics 
Committee prior to any data collection. All participants taking part in the study were 
guaranteed confidentiality and anonymity. Signed consent forms were obtained from 
all participants prior to taking part in the semi-structured interviews. Participants were 
informed of their right to withdraw from the study at any time. This was done both in 
writing and verbally. 
 
RESULTS 
Participants 
A total of fifteen participants (age 22-65 years mean 41 years; 10 female) were 
recruited, 12 via the London newspaper and three via Brunel University. Thirteen 
participants described themselves as ‘White’, one as ‘Asian Pakistani’, and one as 
‘Black Caribbean’. All participants had been prescribed the same brand of EAI 
(EpiPen). Eleven participants reported a previous reaction which warranted the 
administration of epinephrine, however, only seven of these 11 had used the EAI. 
Table 1 provides characteristics of the participants including what they are allergic to, 
whether they have used an EAI in the past, and the severity of their worst ever 
reaction (33). 
Table 1: Characteristics of participants 
Symptoms during worst allergic reaction Severity of 
reaction No. Sex Age Allergenic trigger Used 
EAI? 
1 2 3 4 5 6 7 8 9 10 11 
#1 F 27 All nuts Yes     X X X X X X X Severe 
#2 F 65 Wasp/bee stings No    X   X X X   Severe 
#3 F 22 Insulin, IV cyclazine, wine Yes X X X X X X X X X X X Severe 
#4 M 66 Shell fish & crustaceans No  X  X X X X X X X X Severe 
#5 F 61 Wasp/bee stings Yes   X X X X X X X   Severe 
#6 M 35 Nuts, fish & most fruits Yes X X X X X X X X X X X Severe 
#7 F 52 All nuts No X  X X X X X X X X X Severe 
#8 M 55 Squid & mussels No     X X X     Moderate 
#9 F 30 Peanuts, bee stings, stoned fruits No    X X X X X X   Severe 
#10 M 38 Wasp/bee stings Yes   X X X X X     Moderate 
#11 F 27 Wasp/bee stings, penicillin, eggs No X  X X X  X X    Moderate 
#12 F 22 All nuts Yes   X X X X X  X   Moderate 
#13 F 50 Latex No    X  X X X X X X Severe 
#14 M 36 All nuts No X  X X X X X X X  X Severe 
#15 F 38 Eggs, milk, corned beef Yes   X X X X X X X   Severe 
Key: 
1: Vomiting  2: Abdominal pain            3: Rash  4: Face swelling 5: Tingling/sore mouth  6: Lips/tongue swelling 
7: Throat tightening          8: Breathing difficulties   9: Wheezing 10: Blue around lips 11: Collapse 
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Key themes 
Key themes identified in relation to EAIs included: public acceptability of EAIs; 
previous experiences; carrying the EAI; device design features. Quotes are labelled 
as participant number, and Severity = Severe, moderate or mild (33). Direct quotes 
from participants are included. Square brackets containing text [  ] are used to 
provide information that is required for clarification purposes.  
Public acceptability of EAIs 
Participants identified a number of perceived and observed reactions to EAIs by 
friends and the public. Participants felt that there was a lack of public awareness of 
what an EAI is or indeed what purpose such a device serves in the event of an 
anaphylactic reaction. As a result, there was concern as to how the device may be 
perceived, in terms of its function, but also what conclusions may be drawn, by 
members of the public, about the person who carries such a device. In some cases, 
it was felt that the device may be perceived as some sort of offensive weapon. 
Consequently some individuals expressed a reluctance to use the device in public. 
#15, Severe: I would definitely use it if I’m on my own, but if there’s a group of us 
and that, I wouldn’t.  I wouldn’t use it, no, I wouldn’t do it – I would just…take myself 
away – know that it’s coming on, and just go to the toilet or outside or something and 
just try and ‘style it out’ [laughing – and striking a pose]!  
The perception of the EAI being as a weapon was further extended to the notion of 
the device posing a personal threat to the individual carrying it, which consequently 
caused them to question whether the benefits of carrying the device outweigh the 
potential risks. For example, if members of the public were to come to know that the 
patient was in possession of such a device, it may be used a weapon against them. 
Participant #10 recalled a mugging incident, which caused him to worry for his own 
safety as a result of carrying the EAI. 
#10, Moderate: Em, there’s been a couple of times – I don’t live in the nicest of 
neighbourhoods. There’s been a couple of times where I’ve been mugged, or almost 
mugged, and I’ve thought, “What would happen if they’d used that on me when I 
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didn’t need it?”  So that’s a concern as well, that it could be, in the wrong hands, it 
could be a…it could be an instrument that hinders your life rather than saves it. 
Individuals also suggested that passing through security check-points often 
motivated them not to carry the device on their person at all. Attending football 
matches, night clubs, or passing through airport security typically were considered a 
potential cause of complications. Participant #14 stated that he no longer carries his 
EAI with him to football games, because of the resistance he gets when being 
searched on entering the stadium. 
#14, Severe: Well, when I go to football, once a week... you get searched going into 
every away game, these days, and I didn’t want to be sitting there causing a scene 
because I’ve got an EpiPen, you know, in case I’m going to sort of run on the pitch 
and stab one of the players with it.  That’s obviously what they think.  You’re not 
allowed knives, not allowed anything in, so why not this, you know?   
It was also felt that carrying a drug such as epinephrine on ones person may invite 
others to draw unwarranted and unwanted conclusions that are potentially 
stigmatising, namely seeing the individual as a source of gaining access to a drug 
that could be used for recreational purposes. Such concerns motivated the 
individuals to either not carry the device or take care to conceal it from others. The 
following two quotes exemplify these points respectively. 
#15, Severe: …embarrassment, mm, embarrassment, definitely...it makes me feel like 
I’m a bit labelled as, oh, there’s something wrong with her – it’s obvious there’s 
something a little bit wrong with me.. 
#12, Moderate: I mean, it is a drug...and people will do...do anything for a quick, you 
know, especially for a shot of adrenalin to…  So em, you know, I don’t like to declare 
it. 
Previous experiences 
Prior experiences also impacted on the extent to which the device was seen by 
participants as being of potential value in the treatment of an anaphylactic episode. 
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Participant #9 did unconcerned about not having an EAI with her at all times, largely 
as a result of having survived for 28 years without carrying such a device. 
#9, Severe: To be honest, I don’t think about it. I’ve only had an EpiPen for about two 
years, so I’ve spent the first 28 years of my life without one.  I guess people who are 
younger, who have always religiously carried one, they feel a little bit strange, but, 
for me, it’s quite a recent thing...I don’t think, oh god, I’ve forgotten it or missing 
it...Maybe, subconsciously, I think, well, I got through the last 28 years without one, 
I’ll probably be okay. 
Those with previous experience of using the device successfully reflected that they 
were unsure how effective the device would be prior to first using it and in particular 
whether the dose administered via the EAI would be sufficient to treat the onset of 
the anaphylactic reaction. In the comment below, Participant #1 reflects on her first 
experience of using the device; particularly in the light of having to use two doses to 
gain the desired effect. 
#1, Severe: I wasn’t sure if the EpiPen was going to work or not because I’d never 
used it before...I wasn’t confident, and then, when I had to take the second one, I was 
even less confident, because I was afraid that it wasn’t working [laughing], but then it 
did start to work quite quickly.  And after, that first time, I’ve felt much more 
confident in them.  I sort of feel pretty much totally confident that, if I need it, it will 
work. 
Indeed for individuals that had never used the device, there seemed to be notable 
doubts over whether the EAI had any value in effectively treating an anaphylactic 
episode. For example, Participant #14 reflects on his concern that the dose may be 
too low, and Participant #4 expresses concern that the dose may be too high for 
treatment of a mild reaction. 
#14, Severe: I never carry it around, and I know I should do...but it’s just, when I’ve 
been in hospital, the doctors have always said afterwards that it’s taken quite a lot of 
adrenalin to sort of keep me alive...I always wonder if there’s enough adrenalin in the 
actual EpiPen to actually keep me alive…but the fact is I don’t trust it. I don’t trust to 
see if it would actually work, because I’ve never actually used it.... 
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#4, Severe: What’s a safe dosage of that for someone? You know, because you could 
be having a mild reaction, I suppose, and get nervous or panic, and do it, and if you 
had the wrong…if it was excessive, it could give you a heart attack. At my age, it 
might give you a heart attack.  I don’t know what it could do to you. 
For the inexperienced user, there is confusion as to when the appropriate time is to 
deploy the device given the anxiety and uncertainty around deploying the device ‘in 
error’. 
#11, Moderate: ...because I’m so unsure about how far it needs to get, like do I need 
to be going blue?  You know, if my tongue starts swelling at all, should I use then?  
I’ve not got a clue...I mean I’ve not really had any training in it either.  I got a little 
pamphlet, but that’s not ideal, is it? 
People who had previously used their EAI were more confident about using it again. 
Participant #6, reported to have used the device in excess of 10 times in his lifetime. 
#6, Severe: So yes...there are things that can happen where you mistake it.  However, 
the ambulance staff and the doctors afterwards – “You did the right thing.  You 
thought you had an anaphylactic, and you’ve used that, like you would have in an 
asthma attack, you’d use your [Ventalin] – it makes no difference, you did the right 
thing.”  So I have no fear of using it at any time when I feel that I can’t breathe and 
I’ve got the anxiety...I would use it, regardless, as a precaution. 
Carrying the EAI 
Carrying the device is of course a necessary but not sufficient prerequisite of use.  
Despite it being self-care best practice to carry the EAI at all times (40), some users 
conducted a risk assessment to decide when it was necessary to carry the EAI. In 
many cases participants were willing to delegate responsibility for providing rapid 
treatment of an anaphylactic reaction to the emergency services, particularly when it 
was perceived that such a service was in operation within the local area. Participant 
#3 explains that she would be more likely to carry the device when in rural locations 
or environments where she had less knowledge of the emergency services, as 
opposed to when she was in more urban areas. 
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#3, Severe: I think…I think there’s the reliance of, oh, I’m in the city, I’m going to be 
okay, there’s so many hospitals, there’s ambulances…you’re covered kind of thing, 
compared to if you was in the middle of the mountains in Scotland or something like 
that. 
This was echoed by a number of individuals, who on a day to day basis trusted that 
the emergency services would be available if required, and therefore felt safe not 
carrying the device. However, when abroad on holiday, it was seen as a necessity. 
Other factors that increased this necessity were the potential language barriers that 
may exist when ordering food in a foreign country. Participant #9 reported that, apart 
from being on holiday, it is rare to have it on his person. 
#9, Severe: Very rarely.  When I first got it, I was really good and very disciplined.  
More recently, I can’t remember… I take it on holiday with me, but I’d probably say, 
in terms of percentages, I’d say maybe 5% of the time or something like that. 
Device design features 
Participants drew attention to a number of factors related to the design of EAI 
devices that influenced whether they carried the device or predisposed its use in the 
event of an anaphylactic reaction. Participants commonly complained that the size of 
the device prevents them from carrying it, particularly as it is too big to comfortably fit 
the device into a trouser pocket. Participant #1 reported needing to make special 
consideration to accommodate the device, typically in the form of a bag large enough 
to carry it. 
#1, Severe: The only thing I can think of is making it smaller, because that’s the only 
thing that annoys me.  Because it’s quite long and sort of bulky, I mean, for what it is, 
it means I have to take a bigger bag than I otherwise would, or if I’m trying to sort of 
put it ,you know, you can’t put it in a pocket or somewhere if you’re going to do 
something sporty.   
In addition to the size of the device, the fact that there was no obvious means of 
‘clipping’ it to one’s person as a means of carriage was also noted as a factor that 
predisposed leaving it behind. Participant #4 commented that if the EAI took the form 
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of a standard ballpoint pen, carrying the device would be a simple task easily 
achievable on a day-to-day basis. 
#4, Severe: If you could design one that was like that (picking up a pen from the 
table), there’s a future for you, mate!  If that was the EpiPen, I could just put 
that…you know, go to the football, and just put it in my shirt, like this (clipping it in 
the V of his shirt), but, you know, with these, you can’t do that. 
Many users felt that it would be beneficial to carry the device in the product 
cardboard packaging, as it was felt that there may be crucial information on the 
packet. Participant #7 commented it is not feasible to carry the device in its package. 
#7, Severe: Well, you can’t keep it in the box because it’s huge and it’s ridiculous, 
Toblerone-style affair. Then, you’ve got the plastic tube that it comes in, that you keep 
it in, which the lid bit of it always comes off.  Then, you’ve got the length of it, which 
is too big, the whole thing is too big. 
Participants frequently commented that EAI’s have a surprisingly short use-by date. 
For a device that is ideally used infrequently, users suggested that these dates are 
unrealistically short, often resulting in the need to replace the device having never 
used it. In some cases, use-by dates were been reported to be as short as four 
weeks after the device was dispensed as indicated by Participant #4. 
#4 Moderate: And when they hand one of those over to you...you need to check the 
sell-by date, because quite often, or sometimes, they might give you something which 
has only got four weeks, you know, eight weeks left...Whoever makes these, I think 
they’re aggressive on the sell-by dates. 
As a result of these short expiry dates, users sometimes took the decision to hold-on 
to devices that had clearly passed their expiry date. In a number of cases users 
reported to have been advised by health professionals to ignore the expiry dates, 
being told that the device will still have the required effect as long as the liquid in the 
device does not appear to be cloudy. Participant #4 commented that he has never 
known any of his EAIs to become discoloured or cloudy over 12 years and thus that 
they are safe to use.  
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#12Moderate: I believe the specialist said that they don’t…they never really go out of 
date, but the time not to use it is when it’s discoloured or when there’s sort of 
condensation in the tube. 
#4, Severe: I’ll bring one of my out-of-date ones and say, you know, “I’m putting it in 
the top of your liquor chest” or whatever, I’ve got one in there, in case we ever need 
it.” so they know that there’s a spare around...I’ve got one on my boat, you know, and 
in the glove-box of the car, just in case, you know, and I think they’re probably still 
pretty good. 
Participants reported that typically they were only able to obtain two EAIs on 
prescription at any one time. Therefore, the assumption that the expiry date could be 
ignored, resulted in some participants accumulating several devices over a number 
of years. In order to overcome the awkwardness of carrying the device on one’s 
person, these devices were distributed in a range of locations; in the hope that a 
device would be close at hand should the individual experience an anaphylactic 
reaction. Some of the locations participants reported to store the devices included 
friends or family members houses, in the glove box of the car, and in a desk drawer 
at work.  
Participants suggested that EAIs should be designed in the form of a less 
conspicuous everyday object, such as lipstick or deodorant. This seems to support 
the earlier theme Public acceptability of EAIs, in that participants felt that the EAI 
was perceived as a weapon by members of the public. Participant #15, when 
commenting on how the design of the device may be improved, commented as 
follows. 
#15, Severe: Like a little pouchy thing, you know, like a pretty, like you have for your 
phone, something like that, because it could be a lipstick, you know, a thin lipstick or 
one of them skinny deodorants or what have you, you know?  But it’s so revealing, 
through that glass case, that plastic case, it’s so revealing.  You know, it’s yellow on 
yellow as well, and it’s revealing, you know, like a weapon, sort of. 
Indeed, some participants reported that they already disguise their EAI by carrying 
within an additional container. Some of the containers currently used include a cigar 
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case, a children’s pencil case and a glasses case. In the comment below, Participant 
#12, comments on the use of a glasses case and its function. 
#12Moderate: I just…I just feel it’s…  I don’t really know.  I think I’ve had it in a 
glasses case for so long I don’t really know why anymore.  It’s… for me, it’s just too 
obvious and too… If I’m rifling through my handbag and I have to get it out, people 
are… “What’s that?  Why do you have that?” and then you have to go off into this 
long story and… I don’t, you know…  If I just pop out a glasses case, people think it’s 
a glasses case, and actually, I’ve got my contacts in today, but I do normally wear 
glasses. 
 
DISCUSSION 
With the increasingly central role the patient is expected to play in the delivery of 
their own care (5), there is a need to gain in-depth insights into the barriers that 
currently exist in delivering effective patient self-care and management for specific 
conditions/settings (7). In this study, 15 in-depth interviews were carried out with 
individuals that have been prescribed EAIs for the self-care and management of 
anaphylaxis. Analysis of the interview data aimed to gain detailed insights into the 
barriers that exist to patients adhering to self-care best practice recommendations for 
this condition; the carriage of the device at all times and its deployment when 
necessary. The results revealed four high-level themes: Impact of experience; 
Previous experiences; Carrying the EAI; Device design features. Based on the 
findings of this study, it appears that patients see a number of barriers to carriage 
and use of EAIs. Table 2 summarises the barriers to use and makes some 
recommendations as to how these may be overcome. 
Some barriers to carriage and use may be overcome by improving the knowledge 
and training that is delivered to patients and those around them, including self-
management education which will enable patients to make informed decisions about 
their care (19, 23). Other barriers have implications for education of members of the 
wider community, for example, security staff. Importantly, there are design features 
of the EAIs, that participants found challenging, particularly the size and short shelf 
life. If patients choose to leave their device at home because of its size, the 
  
17 
 
Table 2: Barriers to EAI use and recommendations of how these barriers might be overcome. 
 
Public acceptability of EAIs 
Training/ 
education 
public 
Training/ 
education 
patients 
Device re-
design 
- Reluctance to use in public due to public perceptions X X X 
- Perceived threat to carrier  X X 
- Perceived as weapon by security staff and public X  X 
- Public perceptions of users and embarrassment of patients X X  
Previous experiences    
- Previous experience of survival without device  X  
- Absence of positive life experience using device  X  
- Not knowing when to deploy device  X  
- Lack of knowledge regarding device efficacy and appropriateness of dose  X  
- Perceived fatal consequences of receiving a dose of epinephrine ‘in error’  X  
Carrying the EAI    
- Reliance on emergency services where possible  X  
Device design features    
- Size and shape   X 
- No means of clipping device to clothing   X 
-  Short shelf life X  X 
- Hostile looking device – too easily recognised   X 
 
 
prescription cost is wasted, and the patient is at increased risk in the event of 
anaphylaxis. The short shelf life also needs to be addressed. The current situation of 
short shelf life has cost implications, but is additionally putting patients at risk as they 
choose to attempt to overcome this by relying upon out of date devices. Some 
participants were under the misconception that the out of date device would be fine 
as long as the drug had not become discoloured. Although patients should be 
encouraged to check for discoloration, it must be emphasised that a clear solution is 
not a reliable indication of an adequate drug when the shelf life has been exceeded; 
use of time-expired devices has been associated with fatal cases of anaphylaxis (15, 
41). Participants indicated that they are reluctant to reveal or use an EAI in public. 
Participants felt that the device may be perceived as an offensive weapon, a belief 
that was re-enforced when attempting to pass through security checkpoints. Efforts 
to educate the general public regarding these devices is needed, to improve 
awareness, familiarity and public acceptance of these devices, and to reduce the 
stigma perceived by allergic individuals. However, there also appears to be a need to 
better support the patient and provide them with improved levels of collaborative 
care, as is suggested to be a key enabling factor for patients to deliver effective self-
care (19). Better collaborative care is likely to improve levels of patient self-efficacy 
which in turn would increase patient self-confidence to reach the desired goal (20, 
42), which in this case would be to carry and deploy the device, regardless of 
perceived stigma from members of the public.  
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Improved knowledge and education of patients prescribed an EAI may also help to 
overcome a number of barriers to adherence. The participants in this study were 
recruited from non-medical sources. Some had been prescribed their EAI in primary 
care and others in specialist allergy clinics. The spectrum of training and advice that 
participants had received was therefore diverse, reflecting the reality of patients in 
the UK where allergy services are patchy (43, 44). Clearly, there appears to be a 
need, not only for self-management education (19), but also more traditional factual 
information specific to this condition. Many participants were unclear concerning 
basic information regarding their EAI and treatment of reactions. For example: Which 
symptoms justify the appropriate deployment of the device? How effective is the 
device in the treatment of anaphylaxis? Is the dose of epinephrine appropriate for 
any anaphylactic episode? Are the consequences fatal if a dose of epinephrine is 
received in the absence of anaphylaxis? In some cases, having lived a large 
proportion of their life without an EAI added to the questions of efficacy and indeed 
necessity of the device. Furthermore, some participants preferred to rely on 
emergency services for treatment of anaphylaxis, particularly in urban areas. This is 
a dangerous strategy, since it will delay the administration epinephrine and delayed 
treatment has been associated with fatal anaphylaxis (45). These barriers raise clear 
questions around the nature of training that patients have received, and whether they 
have been provided with appropriate self-management education in line with the 
patient-practitioner paradigm (19). Appropriate self-management education is a key 
factor that ensures that patients are able to make sensible decisions about their 
care, take appropriate action, and feel confident to alter actions as they experience 
changes in their individual circumstances (20, 21). Therefore it is likely that patients 
would benefit from receiving improved self-management education, which may lead 
to improved levels of adherence to self-care and management guidelines.  
A number of participants indicated that a healthcare professional had advised them 
that it is safe to ignore the expiry date. This reflects the need for improved allergy 
training of professionals on very basic aspects of anaphylaxis self-care and 
management. Considerations relating to the device design may improve the number 
of patients who are prepared to carry their device. Adaptations may be made to the 
aesthetic features of the device, so that it appears to be less ‘weapon like’. 
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Participants suggested disguising the EAI, however, there are obvious risks and 
implications of disguising the device, not least the risk of the device not being 
recognised as an EAI by a member of the public, which may result in the patient not 
receiving treatment in the event of an anaphylactic episode. Furthermore, security 
personnel may be even less comfortable with admitting a person carrying a 
disguised ‘weapon’. However, a design that appears less threatening would clearly 
be welcomed. 
Study limitations 
A potential limitation of this study was that participants were only recruited from the 
London area and indeed three of the participants were recruited from the same 
university although participants did span an age range from 22 – 65 years of age, 
and were from a range of ethnic origins. We recognise that the concepts of reliability 
and validity cannot be unproblematically applied to qualitative research data.  
However, in order to enable the reader to make a judgement as to whether the 
results of this study are transferable to other contexts we have sought to apply 
appropriate criteria to the conduct and reporting of this research: sensitivity in the 
interview procedure and protocol to the settings in which auto injectors might be 
used; commitment and rigour in both the data collection and analysis; transparency 
and coherence in the arguments articulated and in considering the impact of these 
findings for policy and practice (38).  
 
Conclusions 
In summary, we have investigated the barriers to effective self-care and 
management of anaphylaxis using EAIs in a qualitative study of adults with allergy. 
The participants had received their allergy care in a variety of healthcare settings. 
Many revealed a poor understanding of how to self-manage a severe allergic 
reaction, despite having been prescribed treatment by a UK doctor. The study 
demonstrates an urgent need for improved education, both in terms of self-
management education and more traditional fact-based education relating to allergy. 
This education is required not only by patients and the general public, but importantly 
by health professionals who advise these patients on self-care and management 
strategies. There also appears to be scope to improve levels of collaborative care 
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provision made available to patients, which may improve levels of patient self-
confidence and self-efficacy. Delayed or incorrect administration of epinephrine and 
failure to carry prescribed EAIs is likely to cause fatalities. Education and training 
may improve the prognosis, but improvements in device design should also be 
addressed if patients are to be convinced to carry and use their EAIs. 
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